Clover Biopharmaceuticals, Ltd. announced that Ms. FUNG Po Ting ("Ms. FUNG") who is a joint company secretary of the Company (the "Joint Company Secretary "), has tendered her resignation as the assistant manager of corporate services of Vistra Corporate Services (HK) Limited, which is the external corporate services provider of the Company. As a result of the aforesaid resignation, Ms. FUNG ceased to act as (i) the Joint Company Secretary; (ii) an authorized representative of the Company pursuant to Rule 3.05 of the Rules (the "Listing Rules") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (the "Authorized Representative"); and (iii) an authorized representative of the Company to accept service of process and notices on behalf of the Company in Hong Kong as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "Process Agent") with effect from December 22, 2021. Following the cessation of Ms. FUNG to act as a Joint Company Secretary, the Board announced that Ms. CHAU Hing Ling ("Ms. CHAU") has been appointed as a Joint Company Secretary, the Authorized Representative and the Process Agent with effect from December 22, 2021. Mr. Brian KREX ("Mr. KREX") will continue to serve as the other Joint Company Secretary.